Anti-beta Amyloid 1-42 antibody (ab10148)

Rabbit polyclonal beta Amyloid 1-42 antibody. Validated in IHC, ICC and tested in Rat, Dog, Human. Cited in 37 publication(s). Independently reviewed in 11 review(s).


  • Product name

    Anti-beta Amyloid 1-42 antibody
    See all beta Amyloid 1-42 primary antibodies
  • Description

    Rabbit polyclonal to beta Amyloid 1-42
  • Host species

  • Specificity

    This antibody is reactive with A Beta 42 and does not cross-react with A beta Amyloid 1-40, full-length APP, sAPP beta or sAPP alpha. We have evaluated this antibody by IHC and have not specifically evaluated reactivity with oligomeric forms of beta amyloid.
  • Tested applications

    Suitable for: IHC-P, IHC-Fr, ICC, IHC-FoFrmore details
  • Species reactivity

    Reacts with: Rat, Dog, Human
  • Immunogen

    Synthetic peptide conjugated to KLH, corresponding to amino acids 33-42 of Human beta Amyloid 1-42.

  • General notes

    Do not store antibody diluted below 0.5 mg/ml.

    We have received positive and negative feedback from customers for the WB application and Mouse as a tested species. WB is not batch-tested application and Mouse is not a batch-tested species for this antibody and we are not able to cover WB and mouse under our Abpromise guarantee.




Our Abpromise guarantee covers the use of ab10148 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P Use at an assay dependent concentration. Retrieve antigens with 70% Formic acid for 10-30 minutes at room temperature before commencing with IHC staining protocol.
IHC-Fr Use at an assay dependent concentration. PubMed: 18673368
ICC Use at an assay dependent concentration. PubMed: 22003387
IHC-FoFr 1/100.


  • Function

    Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Couples to apoptosis-inducing pathways such as those mediated by G(O) and JIP. Inhibits G(o) alpha ATPase activity (By similarity). Acts as a kinesin I membrane receptor, mediating the axonal transport of beta-secretase and presenilin 1. Involved in copper homeostasis/oxidative stress through copper ion reduction. In vitro, copper-metallated APP induces neuronal death directly or is potentiated through Cu(2+)-mediated low-density lipoprotein oxidation. Can regulate neurite outgrowth through binding to components of the extracellular matrix such as heparin and collagen I and IV. The splice isoforms that contain the BPTI domain possess protease inhibitor activity. Induces a AGER-dependent pathway that involves activation of p38 MAPK, resulting in internalization of amyloid-beta peptide and leading to mitochondrial dysfunction in cultured cortical neurons.
    Beta-amyloid peptides are lipophilic metal chelators with metal-reducing activity. Bind transient metals such as copper, zinc and iron. In vitro, can reduce Cu(2+) and Fe(3+) to Cu(+) and Fe(2+), respectively. Beta-amyloid 42 is a more effective reductant than beta-amyloid 40. Beta-amyloid peptides bind to lipoproteins and apolipoproteins E and J in the CSF and to HDL particles in plasma, inhibiting metal-catalyzed oxidation of lipoproteins. Beta-APP42 may activate mononuclear phagocytes in the brain and elicit inflammatory responses. Promotes both tau aggregation and TPK II-mediated phosphorylation. Interaction with overexpressed HADH2 leads to oxidative stress and neurotoxicity.
    Appicans elicit adhesion of neural cells to the extracellular matrix and may regulate neurite outgrowth in the brain.
    The gamma-CTF peptides as well as the caspase-cleaved peptides, including C31, are potent enhancers of neuronal apoptosis.
    N-APP binds TNFRSF21 triggering caspase activation and degeneration of both neuronal cell bodies (via caspase-3) and axons (via caspase-6).
  • Tissue specificity

    Expressed in all fetal tissues examined with highest levels in brain, kidney, heart and spleen. Weak expression in liver. In adult brain, highest expression found in the frontal lobe of the cortex and in the anterior perisylvian cortex-opercular gyri. Moderate expression in the cerebellar cortex, the posterior perisylvian cortex-opercular gyri and the temporal associated cortex. Weak expression found in the striate, extra-striate and motor cortices. Expressed in cerebrospinal fluid, and plasma. Isoform APP695 is the predominant form in neuronal tissue, isoform APP751 and isoform APP770 are widely expressed in non-neuronal cells. Isoform APP751 is the most abundant form in T-lymphocytes. Appican is expressed in astrocytes.
  • Involvement in disease

    Defects in APP are the cause of Alzheimer disease type 1 (AD1) [MIM:104300]. AD1 is a familial early-onset form of Alzheimer disease. It can be associated with cerebral amyloid angiopathy. Alzheimer disease is a neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituent of these plaques is the neurotoxic amyloid-beta-APP 40-42 peptide (s), derived proteolytically from the transmembrane precursor protein APP by sequential secretase processing. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products such as C31 derived from APP, are also implicated in neuronal death.
    Defects in APP are the cause of cerebral amyloid angiopathy APP-related (CAA-APP) [MIM:605714]. A hereditary localized amyloidosis due to amyloid-beta A4 peptide(s) deposition in the cerebral vessels. The principal clinical characteristics are recurrent cerebral and cerebellar hemorrhages, recurrent strokes, cerebral ischemia, cerebral infarction, and progressive mental deterioration. Patients develop cerebral hemorrhage because of the severe cerebral amyloid angiopathy. Parenchymal amyloid deposits are rare and largely in the form of pre-amyloid lesions or diffuse plaque-like structures. They are Congo red negative and lack the dense amyloid cores commonly present in Alzheimer disease. Some affected individuals manifest progressive aphasic dementia, leukoencephalopathy, and occipital calcifications.
  • Sequence similarities

    Belongs to the APP family.
    Contains 1 BPTI/Kunitz inhibitor domain.
  • Domain

    The basolateral sorting signal (BaSS) is required for sorting of membrane proteins to the basolateral surface of epithelial cells.
    The NPXY sequence motif found in many tyrosine-phosphorylated proteins is required for the specific binding of the PID domain. However, additional amino acids either N- or C-terminal to the NPXY motif are often required for complete interaction. The PID domain-containing proteins which bind APP require the YENPTY motif for full interaction. These interactions are independent of phosphorylation on the terminal tyrosine residue. The NPXY site is also involved in clathrin-mediated endocytosis.
  • Post-translational

    Proteolytically processed under normal cellular conditions. Cleavage either by alpha-secretase, beta-secretase or theta-secretase leads to generation and extracellular release of soluble APP peptides, S-APP-alpha and S-APP-beta, and the retention of corresponding membrane-anchored C-terminal fragments, C80, C83 and C99. Subsequent processing of C80 and C83 by gamma-secretase yields P3 peptides. This is the major secretory pathway and is non-amyloidogenic. Alternatively, presenilin/nicastrin-mediated gamma-secretase processing of C99 releases the amyloid beta proteins, amyloid-beta 40 (Abeta40) and amyloid-beta 42 (Abeta42), major components of amyloid plaques, and the cytotoxic C-terminal fragments, gamma-CTF(50), gamma-CTF(57) and gamma-CTF(59).
    Proteolytically cleaved by caspases during neuronal apoptosis. Cleavage at Asp-739 by either caspase-6, -8 or -9 results in the production of the neurotoxic C31 peptide and the increased production of beta-amyloid peptides.
    N- and O-glycosylated. O-linkage of chondroitin sulfate to the L-APP isoforms produces the APP proteoglycan core proteins, the appicans. The chondroitin sulfate chain of appicans contains 4-O-sulfated galactose in the linkage region and chondroitin sulfate E in the repeated disaccharide region.
    Phosphorylation in the C-terminal on tyrosine, threonine and serine residues is neuron-specific. Phosphorylation can affect APP processing, neuronal differentiation and interaction with other proteins. Phosphorylated on Thr-743 in neuronal cells by Cdc5 kinase and Mapk10, in dividing cells by Cdc2 kinase in a cell-cycle dependent manner with maximal levels at the G2/M phase and, in vitro, by GSK-3-beta. The Thr-743 phosphorylated form causes a conformational change which reduces binding of Fe65 family members. Phosphorylation on Tyr-757 is required for SHC binding. Phosphorylated in the extracellular domain by casein kinases on both soluble and membrane-bound APP. This phosphorylation is inhibited by heparin.
    Extracellular binding and reduction of copper, results in a corresponding oxidation of Cys-144 and Cys-158, and the formation of a disulfide bond. In vitro, the APP-Cu(+) complex in the presence of hydrogen peroxide results in an increased production of beta-amyloid-containing peptides.
    Trophic-factor deprivation triggers the cleavage of surface APP by beta-secretase to release sAPP-beta which is further cleaved to release an N-terminal fragment of APP (N-APP).
    Beta-amyloid peptides are degraded by IDE.
  • Cellular localization

    Membrane. Membrane > clathrin-coated pit. Cell surface protein that rapidly becomes internalized via clathrin-coated pits. During maturation, the immature APP (N-glycosylated in the endoplasmic reticulum) moves to the Golgi complex where complete maturation occurs (O-glycosylated and sulfated). After alpha-secretase cleavage, soluble APP is released into the extracellular space and the C-terminal is internalized to endosomes and lysosomes. Some APP accumulates in secretory transport vesicles leaving the late Golgi compartment and returns to the cell surface. Gamma-CTF(59) peptide is located to both the cytoplasm and nuclei of neurons. It can be translocated to the nucleus through association with APBB1 (Fe65). Beta-APP42 associates with FRPL1 at the cell surface and the complex is then rapidly internalized. APP sorts to the basolateral surface in epithelial cells. During neuronal differentiation, the Thr-743 phosphorylated form is located mainly in growth cones, moderately in neurites and sparingly in the cell body. Casein kinase phosphorylation can occur either at the cell surface or within a post-Golgi compartment.
  • Information by UniProt
  • Database links

  • Alternative names

    • A4 antibody
    • A4_HUMAN antibody
    • AAA antibody
    • ABETA antibody
    • ABPP antibody
    • AICD-50 antibody
    • AICD-57 antibody
    • AICD-59 antibody
    • AID(50) antibody
    • AID(57) antibody
    • AID(59) antibody
    • Alzheimer disease amyloid protein antibody
    • Amyloid intracellular domain 50 antibody
    • Amyloid intracellular domain 57 antibody
    • Amyloid intracellular domain 59 antibody
    • APP antibody
    • APPI antibody
    • Beta amyloid protein 42 antibody
    • Beta APP42 antibody
    • Beta-APP40 antibody
    • Beta-APP42 antibody
    • C31 antibody
    • Cerebral vascular amyloid peptide antibody
    • CVAP antibody
    • Gamma-CTF(50) antibody
    • Gamma-CTF(57) antibody
    • Gamma-CTF(59) antibody
    • PN-II antibody
    • PreA4 antibody
    • Protease nexin-II antibody
    • S-APP-alpha antibody
    • S-APP-beta antibody
    see all


  • ab10148 staining beta Amyloid 1-42 in Rat astrocyte cells by ICC/IF (Immunocytochemistry/immunofluorescence). Cells were fixed with paraformaldehyde, permeabilized with methanol and blocked with 5% serum for 1 hour at 4°C. Samples were incubated with primary antibody (1/100) for 18 hours at 37°C. An Alexa Fluor® 594-conjugated Goat anti-rabbit IgG polyclonal (1/200) was used as the secondary antibody.

    See Abreview

  • ab10148 at a 1/50 dilution staining mouse AD brain tissue sections by Immunohistochemistry (Formalin-fixed paraffin-embedded sections). Following heat mediated antigen retrieval, the antibody was incubated with the tissue for 24 hours. Bound antibody was detected using a biotinylated Goat anti-Rabbit antibody.

    This image is courtesy of an Abreview submitted on 15 March 2006.

    See Abreview

  • ab10148 staining mouse skeletal muscle tissue sections by IHC-Fr.  Sections were acetone fixed and blocked in 5% BSA for 30 minutes at RT prior to incubating with ab10148, diluted 1/100, for 12 hours at 4°C. A FITC conjugated goat anti-rabbit antibody, diluted 1/200, was used as the secondary.

    See Abreview


This product has been referenced in:

  • Zhang Y  et al. a-lipoic acid attenuates spatial learning and memory impairment induced by hepatectomy. Exp Ther Med 17:2329-2333 (2019). Read more (PubMed: 30867718) »
  • Baldacci F  et al. Potential Diagnostic Value of Red Blood Cells a-Synuclein Heteroaggregates in Alzheimer's Disease. Mol Neurobiol N/A:N/A (2019). Read more (PubMed: 30826968) »
See all 43 Publications for this product

Customer reviews and Q&As

1-10 of 26 Abreviews or Q&A

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Dog Tissue sections (Brain)
Antigen retrieval step
Yes - 0.05% TritonX
Blocking step
BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 10% · Temperature: 25°C

Abcam user community

Verified customer

Submitted May 21 2018

Immunocytochemistry/ Immunofluorescence
Human Cell (Vascular smooth muscle cells)
Yes - NP40
Vascular smooth muscle cells
Blocking step
BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 3% · Temperature: 21°C

Abcam user community

Verified customer

Submitted Jan 05 2018

Immunohistochemistry (PFA perfusion fixed frozen sections)
Blocking step
Serum as blocking agent for 30 minute(s) · Concentration: 5% · Temperature: 90°C
Antigen retrieval step
Heat mediated - Buffer/Enzyme Used: citrate buffer
Mouse Tissue sections (brain)

Dr. Richard Deyo

Verified customer

Submitted Dec 10 2013

Blocking step
Serum as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 4°C
Rat Cell (Astrocyte)
Yes - methanol

Abcam user community

Verified customer

Submitted Oct 23 2013

Western blot
Loading amount
100 µg
Gel Running Conditions
Reduced Denaturing (15%)
Rat Tissue lysate - whole (brain tissue)
brain tissue
Blocking step
BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 37°C

Abcam user community

Verified customer

Submitted Sep 17 2013

Immunohistochemistry (PFA perfusion fixed frozen sections)
Rat Tissue sections (rat brain)
rat brain
Blocking step
BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5 · Temperature: 37°C

Abcam user community

Verified customer

Submitted Sep 11 2013


Thank you for your inquiry.

I am happy to confirm that ab10148 (Anti-beta Amyloid 1-42 antibody) is tested and guaranteed to work in WB with mouse and human samples.

For more information on protocols used with this antibody please review the following publications:

Richard KL et al. Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid beta 1-42 and delay the cognitive decline in a mouse model of Alzheimer's disease. J Neurosci 28:5784-93 (2008). PubMed: 18509040

Boissonneault V et al. Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer's disease. Brain 132:1078-92 (2009). PubMed: 19151372

Hartz AM et al. Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer's disease. Mol Pharmacol 77:715-23 (2010). WB, IHC-FrFl ; Human . PubMed: 20101004

I can also recommend to review the advise for small proteins:

All proteins are hindered from binding to membranes by SDS but small proteins more so than large proteins. If your protein of interest is small, consider removing SDS from the transfer buffer.
Keep the methanol concentration at 20%.
Please check the pore size of the membrane that is used and make sure it is suitable for small proteins.

I have chosen two secondary antibodies that are suitable for ab10148 and WB:

ab97061 (or use the following:

ab97051 (or use the following:

I hope this information is helpful and wish you good luck for your research.

Read More


This is confusing. ab113316 is a kit not antibody, customer would not be requiring a DAB kit for this.

For ab101854, ab80436 will be a good product.


Read More


Thank you for contacting us.

The kits ab80436 and ab64264, both will be OK to use with ab10148 only because it is rabbit antibody, you can select any one of them. Please note that these kits cannot be used with ab75714 because it is a chicken polyclonal antibody - you would require a anti chicken HRP conjugated antibody.

There are two possibilities one you change ab75714 with mouse or rabbit as host, second buy the HRP conjugated anti rabbit and anti chicken secondary antibodies including DAB reagents.

I hope this information is helpful to you. Please do not hesitate to contact us if you need any more advice or information.

Read More


Thank you for contacting us. To perform IHC-P with fluorescent secondary antibodies, I would recommend the following protocol:

De-paraffinise sections thoroughly in Xylene/synthetic solvent and hydrate through graded series of alcohols. Wash twice in PBS.
To help expose the insoluble beta Amyloid, we recommend performing antigen retrieval with 10% formic acid in distilled water, pH 1.6-2.0 for 10-30 minutes at room temperature.
Incubate sections for1 hourin 10% normal serum from species in which secondary antibody was raised. Tap excess serum off the slides before staining.
Incubate sections in primary antibody for at least 1 hour at room temperature in a humid chamber or overnight at 4°C. For ab10148, we recommend a starting dilution between 1:100-1:500, and a range of 1:300-1:2000 for ab110888.Wash three times in PBS.
Addfluorescentsecondary antibody at recommended dilution (see specific datasheet for details). Incubate for at least 30 minutes at room temperature in the dark. Wash three times in PBS.
Counterstain with DAPI or our CytoPainter dyes:
Mount in aqueous mounting medium.

I hope this helps, please let me know if you need any other information or assistance.

Read More

1-10 of 26 Abreviews or Q&A

For licensing inquiries, please contact

Sign up